Asset
Empasiprubart
argenx SE American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05405361 | phase2 | active_not_recruiting | 2023-01-18 | 2029-09-30 | argenx | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05225675 | phase2 | completed | 2022-03-31 | 2024-06-04 | argenx | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05907096 | phase2 | active_not_recruiting | 2024-02-17 | 2025-10-16 | argenx | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function |
| NCT04532125 | phase1 | completed | 2020-08-03 | 2022-08-26 | argenx | SAD and MAD Study With IV and SC Doses of ARGX-117 |
FDA applications (0)
This company has no applications containing this asset.